Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants

  • Fraile-Ribot, Pablo Arturo
  • Zamorano, Laura
  • Orellana, Rocío
  • del Barrio-Tofiño, Ester
  • Sánchez-Diener, Irina
  • Cortés-Lara, Sara
  • López-Causapé, Carla
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
[Abstract] Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC., The work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Rodiño-Janeiro, Bruno Kotska
  • Cabot, Gabriel
  • Vázquez-Ucha, Juan Carlos
  • Rodríguez-Iglesias, Manuel
  • Galán-Sánchez, Fátima
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: The development of resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of Pseudomonas aeruginosa infections is concerning. Objectives: Characterization of the mechanisms leading to the development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR P. aeruginosa infections. Methods: Four paired ceftolozane/tazobactam- and ceftazidime/avibactam-susceptible/resistant isolates were evaluated. MICs were determined by broth microdilution. STs, resistance mechanisms and genetic context of β-lactamases were determined by genotypic methods, including WGS. The OXA-10 variants were cloned in PAO1 to assess their impact on resistance. Models for the OXA-10 derivatives were constructed to evaluate the structural impact of the amino acid changes. Results: The same XDR ST253 P. aeruginosa clone was detected in all four cases evaluated. All initial isolates showed OprD deficiency, produced an OXA-10 enzyme and were susceptible to ceftazidime, ceftolozane/tazobactam, ceftazidime/avibactam and colistin. During treatment, the isolates developed resistance to all cephalosporins. Comparative genomic analysis revealed that the evolved resistant isolates had acquired mutations in the OXA-10 enzyme: OXA-14 (Gly157Asp), OXA-794 (Trp154Cys), OXA-795 (ΔPhe153-Trp154) and OXA-824 (Asn143Lys). PAO1 transformants producing the evolved OXA-10 derivatives showed enhanced ceftolozane/tazobactam and ceftazidime/avibactam resistance but decreased meropenem MICs in a PAO1 background. Imipenem/relebactam retained activity against all strains. Homology models revealed important changes in regions adjacent to the active site of the OXA-10 enzyme. The blaOXA-10 gene was plasmid borne and acquired due to transposition of Tn6746 in the pHUPM plasmid scaffold. Conclusions: Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support and relebactam. This work was also supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III (ISCIII), through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O. and P14/00059 and P17/01482 to A.B. Support was also provided by: Planes Nacionales de I + D+i 2013-2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth Program 2014-2020. C.G.-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)] and the European Regional Development Fund (ERDF). J.A.-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-Especialización Grant (2019) and by the Rio Hortega Program (ISCIII, CM19/00219). J.C.V.-U. was financially supported by the pFIS Program (ISCIII, PI17/01482). C.L.-M. was financially supported by an IN606A-2019/029 Grant (Xunta de Galicia).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

  • Arca-Suárez, Jorge
  • Vázquez-Ucha, Juan Carlos
  • Fraile-Ribot, Pablo Arturo
  • Lence, Emilio
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Rodríguez-Iglesias, Manuel
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Galán-Sánchez, Fátima
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: Pseudomonas aeruginosa may develop resistance to novel cephalosporin/β-lactamase inhibitor combinations during therapy through the acquisition of structural mutations in AmpC. Objectives: To describe the molecular and biochemical mechanisms involved in the development of resistance to ceftolozane/tazobactam in vivo through the selection and overproduction of a novel AmpC variant, designated PDC-315. Methods: Paired susceptible/resistant isolates obtained before and during ceftolozane/tazobactam treatment were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. Characterization of the novel PDC-315 variant was performed through genotypic and biochemical studies. The effects at the molecular level of the Asp245Asn change were analysed by molecular dynamics simulations using Amber. Results: WGS identified mutations leading to modification (Asp245Asn) and overproduction of AmpC. Susceptibility testing revealed that PAOΔC producing PDC-315 displayed increased MICs of ceftolozane/tazobactam, decreased MICs of piperacillin/tazobactam and imipenem and similar susceptibility to ceftazidime/avibactam compared with WT PDCs. The catalytic efficiency of PDC-315 for ceftolozane was 10-fold higher in relation to the WT PDCs, but 3.5- and 5-fold lower for piperacillin and imipenem. IC50 values indicated strong inhibition of PDC-315 by avibactam, but resistance to cloxacillin inhibition. Analysis at the atomic level explained that the particular behaviour of PDC-315 is linked to conformational changes in the H10 helix that favour the approximation of key catalytic residues to the active site. Conclusions: We deciphered the precise mechanisms that led to the in vivo emergence of resistance to ceftolozane/tazobactam in P. aeruginosa through the selection of the novel PDC-315 enzyme. The characterization of this new variant expands our knowledge about AmpC-mediated resistance to cephalosporin/β-lactamase inhibitors in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O., and P14/00059 and P17/01482 to A.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth program 2014–2020. C.G-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R, C.G-B.), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)], and the European Regional Development Fund (ERDF). E.L. thanks the Xunta de Galicia for his postdoctoral fellowship. J.A-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-especialización Grant (2019) and by the Rio Hortega program (ISCIII, CM19/00219). J.C.V-U. was financially supported by the pFIS program (ISCIII, PI17/01482). M.M-G. was financially supported by a Clara Roy grant (SEIMC) and C.L-M. by IN606A-2019/029.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology

  • del Barrio-Tofiño, Ester
  • Zamorano, Laura
  • Cortés-Lara, Sara
  • López-Causapé, Carla
  • Sánchez-Diener, Irina
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
[Abstract] Objectives: To undertake a Spanish nationwide survey on Pseudomonas aeruginosa molecular epidemiology and antimicrobial resistance. Methods: Up to 30 consecutive healthcare-associated P. aeruginosa isolates collected in 2017 from each of 51 hospitals were studied. MICs of 13 antipseudomonal agents were determined by broth microdilution. Horizontally acquired β-lactamases were detected by phenotypic methods and PCR. Clonal epidemiology was evaluated through PFGE and MLST; at least one XDR isolate from each clone and hospital (n = 185) was sequenced. Results: The most active antipseudomonals against the 1445 isolates studied were colistin and ceftolozane/tazobactam (both 94.6% susceptible, MIC50/90 = 1/2 mg/L) followed by ceftazidime/avibactam (94.2% susceptible, MIC50/90 = 2/8 mg/L). Up to 252 (17.3%) of the isolates were XDR. Carbapenemases/ESBLs were detected in 3.1% of the isolates, including VIM, IMP, GES, PER and OXA enzymes. The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (4.0%). Carbapenemase production varied geographically and involved diverse clones, including 16.5% of ST175 XDR isolates. Additionally, 56% of the sequenced XDR isolates showed horizontally acquired aminoglycoside-modifying enzymes, which correlated with tobramycin resistance. Two XDR isolates produced QnrVC1, but fluoroquinolone resistance was mostly caused by QRDR mutations. Beyond frequent mutations (>60%) in OprD and AmpC regulators, four isolates showed AmpC mutations associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Conclusions: ST175 is the most frequent XDR high-risk clone in Spanish hospitals, but this nationwide survey also indicates a complex scenario in which major differences in local epidemiology, including carbapenemase production, need to be acknowledged in order to guide antimicrobial therapy., This work was supported by MSD (through a grant to A. O.) and by Plan Nacional de I + D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016) and grants PI15/00088 and PI18/00076 co-financed by European Regional Development Fund ERDF ‘A way to achieve Europe’, Operative program Intelligent Growth 2014–2020. The funders had no role in the design, execution, analysis or reporting of the research.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey

  • Del Barrio-Tofiño, Ester
  • Sánchez-Diener, Irina
  • Zamorano, Laura
  • Cortes-Lara, Sara
  • López-Causapé, Carla
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • on behalf of the GEMARA-SEIMC/REIPI Pseudomonas study group
  • Castillo-García, Francisco Javier
  • Seral, Cristina
Objectives: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a Spanish nationwide survey. Methods: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome sequences of 185 representative XDR isolates. O-antigen serotypes (O1–O16) were determined by agglutination using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for in silico serotyping. Results: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most frequent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within serotypes, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6%of XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced (n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was linked to serotype O12. Conclusions: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals.